According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:
1. Bristol Myers Squibb Co (NYSE:BMY)
Bristol Myers Squibb Co (NYSE:BMY) is the top general drug manufacturer stock with a Zen Score of 68, which is 25 points higher than the general drug manufacturer industry average of 43. It passed 25 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock lose -29.96% over the past year, underperforming other general drug manufacturer stocks by -40 percentage points.
Bristol Myers Squibb Co has an average 1 year
price target of $56.08, an upside of 14.62% from Bristol Myers Squibb Co's current stock price of $48.93.
Bristol Myers Squibb Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 12 analysts covering Bristol Myers Squibb Co, 8.33% have issued a Strong Buy rating, 0% have issued a Buy, 83.33% have issued a hold, while 0% have issued a Sell rating, and 8.33% have issued a Strong Sell.
2. Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ) is the second best general drug manufacturer stock with a Zen Score of 60, which is 17 points higher than the general drug manufacturer industry average of 43. It passed 22 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock lose -9% over the past year, underperforming other general drug manufacturer stocks by -19 percentage points.
Johnson & Johnson has an average 1 year
price target of $176.88, an upside of 19.58% from Johnson & Johnson's current stock price of $147.91.
Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Johnson & Johnson, 37.5% have issued a Strong Buy rating, 25% have issued a Buy, 37.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Gilead Sciences (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) is the third best general drug manufacturer stock with a Zen Score of 56, which is 13 points higher than the general drug manufacturer industry average of 43. It passed 20 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock lose -20.63% over the past year, underperforming other general drug manufacturer stocks by -31 percentage points.
Gilead Sciences has an average 1 year
price target of $82.00, an upside of 22.83% from Gilead Sciences's current stock price of $66.76.
Gilead Sciences stock has a consensus Hold recommendation according to Wall Street analysts. Of the 9 analysts covering Gilead Sciences, 11.11% have issued a Strong Buy rating, 11.11% have issued a Buy, 77.78% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.